The Industry Alliance Office (IAO) acting on behalf of Amsterdam Neuroscience is a one-stop-shop for to the pharma- and biotech-industry for basic and translational neuroscience and for clinical trials. The aim is to speed up the development of new therapies and diagnostics for patients suffering from a neurological disorder or mental illness, from bench to bedside.

The IAO was founded in 2013 with the goal to extend and intensify the collaboration between industry and academic research groups within Amsterdam Neuroscience. Since 2013 the IAO has enabled access to scientific excellence, platform technologies, brain imaging infrastructure, and patient cohorts and material.

This is always based on a disease-orientated approach: Neurodegeneration (AD, FTD, Lewy Body Dementia and Vascular Cognitive Impairment), Neuro-inflammation (MS), Neuro-infection (Meningitis, Chronic Inflammatory Demyelinating Polyneuropathy), Neurovascular Disorders and Neuropsychiatry (Anxiety and Depression, Psychosis, OCD, PTSD and SZ). We have a track record of clinical trials and translational research projects with over 120 companies.

Infographic of the Industry Alliance Office